Zhou Jianwei, M.D.

Position:Vice Chair of Gynecology


Medical School:Zhejiang University School of Medicine, China

Academic Rank:Chief Physician


Clinical / Research Interests

Diagnosis and treatment of endometriosis and gynecological tumors with minimally invasive techniques, especially the laparoscopic surgery for difficult hysterectomy, complex pelvic endometriosis and ovarian cancer.

Professional Highlights

Best Surgical Skill Award, National Experience Sharing Conference on Laparoscopic Surgery

Operation Video Contest of the First Annual Meeting of Gynecological Oncology of Zhejiang Medical Association, Second Prize

Professional Award for Science and Technology Innovation of Zhejiang Province, Third Prize

Professional Appointments

Vice Chairman, Pelvic Floor Rehabilitation Committee, China Maternal and Child Health Association

Member, Gynecological Oncology Group, China Medical Care Exchange Promotion Association

Member, Tumor Reproduction Branch, China Healthy Birth Science Association

Member, Gynecological Oncology Branch, Zhejiang Medical Association

Deputy Leader, Colposcopy and Cervical Pathology Group, Gynecological Oncology Branch, Zhejiang Medical Association

Deputy Director, Day Surgery Diagnosis and Treatment Committee, Zhejiang Maternal and Child Health Association

Member, Minimally Invasive Group, Chinese Medical Association

Member, Zhejiang Endometriosis Cooperative Group

Member, 7th Professional Committee of Obstetrics and Gynecology, Zhejiang Society of Traditional Chinese and Western Medicine

Education Experience

Research Summary

The tumor microenvironment is a hot spot in the field of immune research. The M1 Macrophages show high pro-inflammatory and antigen-presenting abilities and host immune scavenging activity against tumor cells. Dr. Zhou's previous study found that LincAM1T expression was significantly up-regulated in M1 macrophages and LincAM1T was hypothesized to inhibit epithelial ovarian cancer by inducing macrophage M1 polarization. Thus, Dr. Zhou's team is trying to explore the molecular mechanism by which LincAM1T induces macrophage M1 polarization to inhibit the progression of epithelial ovarian cancer.


Pan T#, Liu J#, Xu S, Yu Q, Wang H, Sun H, Wu J, Zhu Y, Zhou J*, Zhu Y*. ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells. Theranostics. 2020, 10:516-536.

Yu S#, Shen J#, Fei J, Zhu X, Yin M, Zhou J*. KNDC1 Is a Predictive Marker of Malignant Transformation in Borderline Ovarian Tumors. Oncotargets Therapy. 2020,13: 709–718. 

Zhu Y, Zhang Z, Jiang Z, Liu Y, Zhou J*. CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment. Front Genet. 2020 Apr 30;11:369.

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, Zhai L, Sadhukhan A, Zhou J*. Tumor associated macrophages (TAMs): a critical activator in ovarian metastasis. Oncotargets Therapy. 2019, 12:8687-8699. 

Shen J, Yu S, Sun X, Yin M, Fei J, Zhou J*. Identification of Key Biomarkers Associated With Development and Prognosis in Patients With Ovarian Carcinoma: Evidence From Bioinformatic Analysis. J Ovarian Res. 2019 Nov 15;12(1):110.

Shen J, Zhu X, Fei J, Shi P, Yu S, Zhou J*. Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect. Oncotargets Therapy. 2018, 11: 2831-2841. 

Zhang W#, Fei J#, Yu S, Shen J, Zhu X, Sadhukhan A, Lu W*, Zhou J*. LINC01088 inhibits tumorigenesis of ovarian epithelial cells by targeting miR-24-1-5p. Sci Rep. 2018, 8:2876. 

Lin H, Ding Z, Kota VG, Zhang X, Zhou J*. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Oncotarget. 2017, 8:46601-46610.

Current Program

Find People

Search by Family Name

Find A Department

Search by Departments